Arcturus Therapeutics (NASDAQ:ARCT) Downgraded to Sell Rating by Wall Street Zen

Arcturus Therapeutics (NASDAQ:ARCT) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Saturday.

ARCT has been the topic of several other reports. Guggenheim cut shares of Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Arcturus Therapeutics in a research report on Friday. HC Wainwright reaffirmed a “neutral” rating and set a $12.00 price target (down from $60.00) on shares of Arcturus Therapeutics in a report on Friday. Leerink Partners reduced their price objective on Arcturus Therapeutics from $63.00 to $54.00 and set an “outperform” rating on the stock in a research note on Friday, August 22nd. Finally, Citigroup cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating and decreased their target price for the stock from $49.00 to $12.00 in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $31.71.

Arcturus Therapeutics Price Performance

Arcturus Therapeutics stock opened at $11.22 on Friday. The firm has a market capitalization of $304.74 million, a P/E ratio of -5.03 and a beta of 2.39. The stock has a fifty day moving average price of $18.72 and a two-hundred day moving average price of $14.76. Arcturus Therapeutics has a 52-week low of $8.04 and a 52-week high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, August 11th. The biotechnology company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.77. The company had revenue of $28.30 million for the quarter, compared to the consensus estimate of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, equities research analysts predict that Arcturus Therapeutics will post -2.22 EPS for the current fiscal year.

Institutional Trading of Arcturus Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ARCT. Millennium Management LLC bought a new stake in Arcturus Therapeutics during the 1st quarter worth about $4,892,000. Vestal Point Capital LP bought a new stake in shares of Arcturus Therapeutics during the first quarter worth approximately $2,243,000. Diversify Advisory Services LLC lifted its holdings in Arcturus Therapeutics by 1,136.1% in the second quarter. Diversify Advisory Services LLC now owns 222,500 shares of the biotechnology company’s stock valued at $2,895,000 after buying an additional 204,500 shares during the period. ARK Investment Management LLC boosted its stake in Arcturus Therapeutics by 3.9% in the first quarter. ARK Investment Management LLC now owns 2,008,480 shares of the biotechnology company’s stock valued at $21,270,000 after acquiring an additional 74,629 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new stake in Arcturus Therapeutics during the 1st quarter worth $701,000. 94.54% of the stock is currently owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.